1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Nektar Turns Up The Heat On Partnering Talks For NKTR-181

 
• By Jessica Merrill

The company reported positive Phase III efficacy data on the first-in-class mu-opioid agonist molecule designed to provide pain relief without the euphoria that leads to addiction with standard opioids.

Mortarandpestle_1220x675

Nektar Therapeutics is seeking an experienced pain marketing partner to bring its first-in-class mu-opioid agonist NKTR-181 to market after a positive Phase III data readout. CEO Howard Robin detailed regulatory and partnering plans for the drug in a conference call March 20.

The novel mu-opioid agonist could have appeal to drug makers currently working in pain, given growing concerns over the use...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.